Advertisement
AMPH vs EBS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a Buy and EBS is a StrongBuy.
Aroon Indicator for AMPH shows an upward move is likely
AMPH's Aroon Indicator triggered a bullish signal on October 07, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 241 similar instances where the Aroon Indicator showed a similar pattern. In 201 of the 241 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMPH as a result. In 59 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The 50-day moving average for AMPH moved above the 200-day moving average on October 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMPH advanced for three days, in 259 of 332 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMPH moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 30 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 67 cases where AMPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for AMPH turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 30 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
AMPH broke above its upper Bollinger Band on September 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. AMPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.451) is normal, around the industry mean (11.138). P/E Ratio (15.057) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.640) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.522) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Aroon Indicator for EBS shows an upward move is likely
EBS's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 177 similar instances where the Aroon Indicator showed a similar pattern. In 149 of the 177 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
EBS moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EBS crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in 208 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for EBS moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
EBS broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.931) is normal, around the industry mean (11.138). P/E Ratio (-1.824) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
AMPH | EBS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 88 | 100 | |
SMR RATING 1..100 | 69 | 97 | |
PRICE GROWTH RATING 1..100 | 38 | 75 | |
P/E GROWTH RATING 1..100 | 7 | 98 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (42) in the Biotechnology industry is in the same range as AMPH (57) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.
AMPH's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as EBS (100) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.
AMPH's SMR Rating (69) in the Pharmaceuticals Other industry is in the same range as EBS (97) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.
AMPH's Price Growth Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (75) in the Biotechnology industry. This means that AMPH’s stock grew somewhat faster than EBS’s over the last 12 months.
AMPH's P/E Growth Rating (7) in the Pharmaceuticals Other industry is significantly better than the same rating for EBS (98) in the Biotechnology industry. This means that AMPH’s stock grew significantly faster than EBS’s over the last 12 months.
| AMPH | EBS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 3 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 65% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| Advances ODDS (%) | 8 days ago 78% | 24 days ago 79% |
| Declines ODDS (%) | 22 days ago 68% | 2 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 52% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMPH’s FA Score shows that 1 FA rating(s) are green while EBS’s FA Score has 0 green FA rating(s).
- AMPH’s FA Score: 1 green, 4 red.
- EBS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMPH’s TA Score shows that 4 TA indicator(s) are bullish while EBS’s TA Score has 5 bullish TA indicator(s).
- AMPH’s TA Score: 4 bullish, 5 bearish.
- EBS’s TA Score: 5 bullish, 5 bearish.
Price Growth
AMPH (@Pharmaceuticals: Generic) experienced а +0.46% price change this week, while EBS (@Pharmaceuticals: Generic) price change was -10.27% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
AMPH is expected to report earnings on Nov 05, 2026.
EBS is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
EBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | -1.43% | ||
| SIGA - EBS | 40% Loosely correlated | -0.95% | ||
| COLL - EBS | 40% Loosely correlated | -1.36% | ||
| AMPH - EBS | 37% Loosely correlated | +1.00% | ||
| XERS - EBS | 33% Loosely correlated | -3.10% | ||
| VTRS - EBS | 32% Poorly correlated | -1.07% | ||
More | ||||